Showing results (271-280 of 3,703) with videos related to
Sort By:
Pageof 371
Pharmacology & Therapeutics|March 30, 2017
Reviving the guardian of the genome: Small molecule activators of p53Daniel Nguyen, Wenjuan Liao, Shelya X Zeng, et al.Pharmacology & Therapeutics|May 1, 2014
Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndromeNina Schlueter, Anita de Sterke, Diana M Willmes, et al.Pharmacology & Therapeutics|April 8, 2014
Epigenetic targets and drug discovery: part 1: histone methylationYanli Liu, Ke Liu, Su Qin, et al.Pharmacology & Therapeutics|April 8, 2014
Stromal derived factor 1α: a chemokine that delivers a two-pronged defence of the myocardiumDaniel I Bromage, Sean M Davidson, Derek M YellonPharmacology & Therapeutics|February 13, 2014
Inflammasome: cancer's friend or foe?Michela Terlizzi, Vincenzo Casolaro, Aldo Pinto, et al.Pharmacology & Therapeutics|March 18, 2014
MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier functionKenji Ikemura, Takuya Iwamoto, Masahiro OkudaPharmacology & Therapeutics|March 25, 2014
Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testingDaniel Sinnecker, Karl-Ludwig Laugwitz, Alessandra MorettiPharmacology & Therapeutics|February 23, 2017
Theranostic of biopharmaceuticalsBenjamin Chaigne, Hervé WatierPharmacology & Therapeutics|February 23, 2017
The impact of in silico screening in the discovery of novel and safer drug candidatesDidier RognanPharmacology & Therapeutics|February 23, 2017
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomasCindy Neuzillet, Benoît Rousseau, Hemant Kocher, et al.Pageof 371